Neuome Peptides Pte Ltd - Investor Presentation

Welcome & Introductory Remarks - Ravi Govindan (Co-Founder)

Disrupting the Diagnostics Industry: An overview of Neuome Peptides’ Rapid Diagnostics Technologies and Product Road Map - Dr. Rajanikanth Vangala (Chief Scientific Officer)

• Convergence of Science - An overview of how the use peptides differentiates from the use of standard antibodies with reference to specificity, sensitivity, speed, and accuracy.
• TruCov - An introduction to Neuome Peptides’ platform technology (InstaDetect), using our peptide-based COVID-19 testing devices as an illustrative example.
• TruHeart - An overview of the cardiac biomarker assay platform, TruHeart, as an illustrative example of the adaptability of InstaDetect.
• Clinical Trial Plan, Product Progression and Regulatory Approvals - An update on the ongoing and upcoming clinical trials, product progression and regulatory approvals.

Neuome Peptides Revenue Potential, Valuation and Fundraising Objectives - Ravi Govindan

• Revenue Potential: Neuome Peptides revenue potential with reference to the market size of the relevant biomarkers for its current and most immediate pipeline products.
• Fundraising Objectives: An overview of the fundraising objectives in this round, as well as our intended use of funds.

Q&A - Dr. Rajanikanth Vangala/Ravi Govindan

Closing Remarks - Dr. Rajanikanth Vangala/Ravi Govindan